The company intends to present research for the device during the event’s Startup Showcase next month. It developed the pocket-sized, single-cell, micro-electro-mechanical A1C analysis device, agnostic to hemoglobin variants, to deliver faster, more reliable results for people with diabetes.
Seattle-based Orange Biomed expects its rapid A1C testing device to receive marketing clearance in 2025. The company featured in Drug Delivery Business News’ list of 11 diabetes startups you need to know last year.
“Advancing microfluidic diagnostic technology, we developed the world’s first portable and reusable A1C testing system, agnostic to hemoglobin variants. It is as accurate as lab equipment and as convenient as a typical glucometer,” said Yeaseul Park, CEO of Orange Biomed.
Orange Biomed’s technology leverages advanced microfluidics to perform single-cell analysis of red blood cells. It delivers rapid, lab-accurate A1C results from one drop of blood, the company says. According to the company, it improves upon existing portable A1C meters with enhanced accuracy in point-of-care settings and reliable results for those who find it challenging to obtain accurate readings from traditional at-home tests.
Dr. Eunyoung Park, engineering team director at Orange Biomed said the approach enables highly precise analysis, even with inconsistent sample sizes of one drop of blood.
“This easier approach could reshape diabetes management and diagnostics in the long term, making effective testing more accessible in everyday healthcare settings and for patients on the go,” Eunyoung Park said.
